In today’s pharmaceutical outsourcing market, speed is no longer just about available capacity. It is about how quickly a sponsor and CDMO can make sound technical decisions when materials, vendors, specifications, and timelines collide.
Across the CDMO world, supply chain resilience has become one of the biggest priorities shaping sponsor decisions. Outsourcing demand remains strong, and the oral solid dosage CDMO market is projected to grow from $42.38 billion in 2026 to $57.18 billion by 2031, according to Mordor Intelligence. For sponsors developing or transferring oral solid and liquid dose products, one of the most practical ways to reduce risk is also one of the easiest to underestimate: excipient strategy.
At Mikart, our work across pharmaceutical development, analytical services, manufacturing, and packaging gives us a clear view into how early material decisions can affect project timelines. Excipient selection is not just a formulation decision. It can influence sourcing, quality review, analytical testing, technology transfer, and commercial readiness.
Why Excipient Flexibility Matters
An excipient may seem like a small part of the formulation, but the wrong sourcing strategy can create significant project delays.
A technically appropriate excipient still needs to be available in the right grade, from the right supplier, with the right documentation, and within the right timeline. For sponsors moving through pre-formulation, formulation development, or site and technology transfer, these details can determine whether a project moves efficiently or stalls.
This is especially important as sponsors look for CDMO partners that can support both development flexibility and supply assurance. A resilient strategy does not mean lowering standards. It means identifying which material requirements are truly critical to product quality and which may allow scientifically justified flexibility.
The Hidden Cost of Rigid Material Requirements
Many sponsors enter a project with preferred excipient vendors, legacy specifications, or historical material choices already in place. Sometimes those requirements are essential. Other times, they may reflect prior supplier relationships or older product decisions that have not been revisited.
That distinction matters.
If a CDMO already has an equivalent material available, but the sponsor requires a specific vendor, custom grade, or narrow specification, the project may need to wait for procurement, documentation, testing, and qualification activities. In some cases, a material may be out of stock, discontinued, or available only with a long lead time.
For oral solid dose programs, excipient choices can affect manufacturability, compression, flow, dissolution, stability, and scale-up. For oral liquid and suspension products, excipients may influence solubility, viscosity, preservation, color, flavor, and patient acceptability. Mikart supports a range of dosage forms, including oral solids, liquids and suspensions, capsules, tablets, powder-in-bottle formats, and specialized pediatric and geriatric dosage forms.
Excipient Strategy Is a Quality Decision
Excipient selection should always be evaluated through a technical, regulatory, and quality lens.
The FDA’s Inactive Ingredient Database is one resource sponsors may use when evaluating inactive ingredients used in approved drug products. FDA guidance also explains how the database can support drug product development decisions. The International Pharmaceutical Excipients Council, or IPEC, has emphasized that excipient supplier qualification is fundamental to securing the pharmaceutical supply chain through its Qualification of Excipients for Use in Pharmaceuticals guide.
For sponsors, this means supplier choice should not be based only on familiarity or price. It should also consider:
- Material availability
- Grade and compendial status
- Supplier documentation
- Change-control expectations
- Residual solvent or impurity profile
- Analytical testing requirements
- Regulatory strategy
- Backup supplier options
A CDMO with integrated development, analytical, quality, supply chain, and manufacturing experience can help sponsors evaluate these factors before they affect the critical path.
What Sponsors Should Ask Before Tech Transfer
Before locking in a vendor or specification, sponsors should ask:
Is this excipient source technically required, or is it simply preferred?
Is the material already qualified or commonly used by the CDMO?
Could an equivalent grade reduce lead time without compromising quality?
Are supplier documents complete and current?
Would a second-source strategy reduce risk?
Could qualification activities begin earlier?
Will the material choice affect analytical method development, validation, or release testing?
These questions are especially important during analytical method development, where testing methods need to support reliable release, stability, and regulatory expectations. Material choices made early in development can have downstream effects on testing, documentation, and commercialization.
The CDMO’s Role in Supply Chain Resilience
A strong CDMO should do more than manufacture the product. It should help sponsors identify preventable risks before they affect the timeline.
For small molecule oral solid and liquid programs, that means supporting:
Formulation development
Selecting excipients that support manufacturability, stability, performance, and patient needs.
Technology transfer
Comparing current materials and specifications against available CDMO options.
Analytical strategy
Understanding how excipient choices may affect testing, validation, and release.
Regulatory support
Helping sponsors evaluate when flexibility is possible and when additional justification may be required.
Commercial readiness
Planning for supplier continuity, documentation, scale-up, and repeatable manufacturing.
This is where an experienced partner can create meaningful value. Mikart’s capabilities span pharmaceutical manufacturing, formulation development, analytical method development, site and technology transfers, and packaging support for oral solid and non-sterile oral liquid drug products.
Resilience Starts Before There Is a Shortage
The best time to build supply chain resilience is not after a material becomes unavailable. It is during formulation development, supplier selection, and tech transfer planning.
For sponsors, that means building flexibility into the program early. For CDMOs, it means helping customers understand the tradeoffs between technical performance, quality requirements, supplier availability, and project speed.
The CDMO market will continue to evolve, but one thing is clear: the strongest sponsor-CDMO relationships will be built on early alignment, practical flexibility, and shared visibility into risk.
For oral solid and liquid dose programs, excipient strategy is one of the most actionable places to start.
A better question for sponsors is no longer simply, “Can this CDMO make our product?”
It is: Can this CDMO help us build a smarter, more resilient path to market?
Ready to Strengthen Your Oral Solid or Liquid Dose Program?
Mikart partners with pharmaceutical companies to support development, technology transfer, analytical testing, manufacturing, and packaging strategies designed to reduce risk from development through commercialization.
Contact Mikart to discuss how we can support your next oral solid or liquid dose program.